A scoping study to identify opportunities to advance the ethical implementation and scale-up of HIV treatment as prevention: Priorities for empirical research

BMC Medical Ethics

Volumn 15, Issue 1, 2014, Pages

  Knight, Rod ^a   Small, Will ^b   Pakula, Basia ^a   Thomson, Kimberly ^a   Shoveller, Jean ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; EMPIRICAL RESEARCH; ETHICS; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PUBLIC HEALTH; RESEARCH;

ANTI-HIV AGENTS; DELIVERY OF HEALTH CARE; EMPIRICAL RESEARCH; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH PRIORITIES; HIV INFECTIONS; HUMANS; MALE; PUBLIC HEALTH; RESEARCH;

EID: 84908376275     PISSN: None     EISSN: 14726939     Source Type: Journal    
DOI: 10.1186/1472-6939-15-54     Document Type: Article

References (69)

1. Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. Chang LW, Serwadda D, Quinn TC, Wawer MJ, Lancet Infect Dis 2013 13 65 76 10.1016/S1473-3099(12)70273-6 23257232
2. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG, Lancet 2009 373 48 57 10.1016/S0140-6736(08)61697-9 19038438
3. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Montaner J, Lima VD, Barrios R, Yip B, Wood E, Lancet 2010 376 523 539
4. High coverage of ART Associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML, Science 2013 339 966 971 10.1126/science.1228160 23430656
5. Prevention of HIV-1 infection with early antiretroviral therapy. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JHS, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, et al. N Engl J Med 2011 365 493 505 10.1056/NEJMoa1105243 21767103
6. Treatment as prevention: a double hat-trick. Montaner JS, Lancet 2011 378 208 209 10.1016/S0140-6736(11)60821-0 21763923
7. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. Das M, Chu PL, Santos G-M, Scheer S, Vittinghoff E, McFarland W, Colfax GN, PLoS One 2010 5 11068 10.1371/journal.pone.0011068 20548786
8. Articulating a rights-based approach to HIV treatment and prevention interventions. Barr D, Amon JJ, Clayton M, Curr HIV Res 2011 9 396 404 10.2174/157016211798038588 21999775
9. Clinical uncertainties, health service challenges, and ethical complexities of HIV "Test-and-Treat": a systematic review. Kulkarni SP, Shah KR, Sarma KV, Mahajan AP, Am J Public Health 2013 103 14 e23
10. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Enron J, Chen YQ, Wang L, Ou S, Anderson M, McCauley M, Gamble T, Kumarasamy N, Hakim JG, Kumwenda J, Pilotto JHS, Godbole SV, Chariyalertsak S, Gonçalves De Melo M, Mayer KH, Eshleman SH, Piwowar-Manning E, Makhema J, Mills LA, Panchia R, Sanne I, Gallant J, Hoffman I, Taha TE, Nielsen-Saines K, Celentano D, et al. Lancet 2014 14 281 290 10.1016/S1473-3099(13)70692-3
11. HIV treatment as prevention and the role of applied social science research. Small W, Kerr T, J AIDS Clin Res 2013 02 102e
12. Coggon J, What Makes Health Public? Cambridge: Cambridge University Press 2012
13. Scoping studies: towards a methodological framework. Arksey H, O'Malley L, Int J Soc Res 2005 8 1 32 10.1080/13645570500046624 (Pubitemid 40322703)
14. Scoping studies: advancing the methodology. Levac D, Colquhoun H, O'Brien KK, Implement Sci 2010 5 69 10.1186/1748-5908-5-69 20854677
15. Advancing population and public health ethics regarding HIV testing: a scoping review. Knight R, Shoveller J, Greyson D, Kerr T, Gilbert M, Shannon K, Crit Publ Health 2014 24 283 295 10.1080/09581596.2013.800188
16. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? McAuley L, Pham B, Tugwell P, Moher D, Lancet 2000 356 1228 1231 10.1016/S0140-6736(00)02786-0 11072941
17. University of York. Centre for Reviews and Dissemination, Systematic Reviews Toronto 2009
18. Demonstrating rigor using thematic analysis: a hybrid approach of inductive and deductive coding and theme development. Fereday J, Muir-Cochrane E, Int J Qual Meth 2008 5 80 92
19. Treating our way out of the HIV pandemic: could we, would we, should we? Garnett GP, Baggaley RF, Lancet 2009 373 9 11 10.1016/S0140-6736(08)61698-0 19038439
20. The ethical implications of "treatment as prevention" in the United States. Krellenstein J, Strub S, HIV/AIDS Policy Law Rev 2012 16 11 14
21. Ethics of ARV based prevention: treatment-as-prevention and PrEP. Haire B, Kaldor JM, Dev World Bioeth 2013 13 63 69 10.1111/dewb.12026 23594312
22. HIV treatment as prevention: issues in economic evaluation. Bärnighausen T, Salomon JA, Sangrujee N, PLoS Med 2012 9 1001263 10.1371/journal.pmed.1001263 22802743
23. Treatment as prevention: preparing the way. Williams B, Wood R, Dukay V, Delva W, Ginsburg D, Hargrove J, Stander M, Sheneberger R, Montaner J, Welte A, JIAS 2011 14 6
24. Controlling the HIV pandemic with antiretrovirals-treatment as prevention and pre-exposure prophylaxis-consensus statement. International Association of Physicians in AIDS Care, 2012 http://www.iapac.org/tasp-prep/assets/TPSlon12- consensus.pdf ]
25. Emerging issues in today's HIV response: debate 6-treatment as prevention. USAID and the World Bank, 2012 http://www.aidstar-one.com/events/ emerging-issues-todays-hiv-response-debate-series/debate-six-treatment- prevention ]
26. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, Harrigan PR, Lancet 2006 368 531 536 10.1016/S0140-6736(06) 69162-9 16890841 (Pubitemid 44142776)
27. Treatment as prevention: Bob Leahy in conversation with James Wilton. Canadian AIDS Treatment and Information Exchange, 2013 http://www.catie.ca/en/ prevention/treatment-prevention-bob-leahy-conversation-james-wilton ]
28. Antiretroviral resource allocation for HIV prevention. Singh JA, AIDS 2013 27 863 865 10.1097/QAD.0b013e32835f2b30 23698059
29. Treatment as Prevention: Protecting individual autonomy. Sonnabend J, 2010 http://joseph-sonnabend.com/category/b-prevention-of-hivaids/treatment-as- prevention-protecting-individual-autonomy/
30. USPHS guidelines: We need reliable evidence to justify an earlier start of anti-retroviral therapy. Sonnabend J, 2010 [ http://joseph-sonnabend.com/ category/c-treatment-of-hiv-disease/usphs-guidelines-we-need-reliable-evidence- to-justify-an-earlier-start-of-anti-retroviral-therapy-may-2010/ ]
31. Consultation on antiretroviral treatment for prevention of HIV transmission. World Health Organization, 2009 http://www.who.int/hiv/topics/ artforprevention/Artmeetingreport.pdf ]
32. Separate goals, converging priorities: on the ethics of treatment as prevention. Ostmann F, Saenz C, Dev World Bioeth 2013 13 57 62 10.1111/dewb.12021 23800304
33. Given financial constraints, it would be unethical to divert antiretroviral drugs from treatment to prevention. Macklin R, Cowan E, Health Aff 2012 31 1537 1544 10.1377/hlthaff.2012.0071
34. Treatment-as-prevention needs to be considered in the just allocation of HIV drugs. Haire B, Am J Bioeth 2011 11 48 50
35. Clinical uncertainties, health service challenges, and ethical complexities of HIV "Test-and-Treat": a systematic review. Kulkarni SP, Shah KR, Sarma KV, Mahajan AP, Am J Public Health 2013 103 14 23 10.2105/AJPH.2012.301119 23153160
36. Reaping the prevention benefits of highly active antiretroviral treatment. Forsyth AD, Valdiserri RO, Curr Opin HIV AIDS 2012 7 111 116 10.1097/COH.0b013e32834fcff6 22227586
37. Antiretroviral therapy for prevention of HIV and tuberculosis: a promising intervention but not a panacea. McNairy ML, Howard AA, El-Sadr WM, JAIDS 2013 63 200 S207 23764636
38. Antiretrovirals for HIV prevention: translating promise into praxis. Mayer KH, Lancet 2011 378 206 208 10.1016/S0140-6736(11)61056-8 21763922
39. HPTN 052 and the future of HIV treatment and prevention. Cates W, Lancet 2011 378 224 225
40. Test and treat in HIV: success could depend on rapid detection. Cohen T, Corbett EL, Lancet 2011 378 204 206 10.1016/S0140-6736(11)60896-9 21684592
41. Antiretroviral therapy for prevention is a combination strategy. McNairy ML, Cohen M, El-Sadr WM, Curr HIV/AIDS Rep 2013 10 152 158 10.1007/s11904-013- 0152-1
42. Biomedical strategies for human immunodeficiency virus (HIV) prevention? A new paradigm. Chan R, Ann Acad Med Singapore 2012 41 595 601 23303118
43. The devil in the details: thorough assessment of evidence and ethics is needed in evaluating new HIV prevention methods. Dawson L, Am J Bioeth 2012 12 33 34
44. Treatment as prevention: recognising the creative potential of antiretroviral medications. Pacho A, Somatosphere http://somatosphere.net/2012/ 10/treatment-as-prevention-recognising-the-creative-potential-of-antiretroviral- medications.html ]
45. Editorial: treatment as prevention for HIV. Lancet Infectious Diseases, Lancet Infect Dis 2011 11 651 10.1016/S1473-3099(11)70219-5 21867945
46. Follow the condoms and needles: what previous public health interventions teach us about future deployments of an HIV vaccine. Canadian AIDS Society, 2011 [ http://www.cdnaids.ca/follow-the-condoms-and-needles ]
47. Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs. Gupta RK, Wainberg MA, Brun-Vezinet F, Gatell JM, Albert J, Sonnerborg A, Nachega JB, J Infect Dis 2013 207 101 S106 10.1093/infdis/jit108 23687287
48. Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa. Bärnighausen T, Tanser F, Dabis F, Newell M-L, Curr Opin HIV AIDS 2012 7 140 150 10.1097/COH. 0b013e32834fc1df 22248917
49. Antiretroviral treatment for prevention. United Nations AIDS, 2009 http://www.unaids.org/en/resources/presscentre/featurestories/2009/november/ 20091106artforhivprev/ ]
50. Prevention in focus: views from the front lines: treatment as prevention. Canadian AIDS Treatment Information Exchange, 2010 http://www.catie.ca/en/pif/ spring-2010/views-front-lines-treatment-prevention ]
51. British Columbia's 'seek and treat' strategy: a cautionary tale on privacy rights and informed consent for HIV testing. Vonn M, HIV AIDS Policy Law Rev 2012 16 1 4
52. Remedicalizing an epidemic: from HIV treatment as prevention to HIV treatment is prevention. Nguyen VK, Bajos N, Dubois-Arber F, O'Malley J, Pirkle CM, AIDS 2011 25 291 293 10.1097/QAD.0b013e3283402c3e 20962615
53. Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: balancing methodological rigor and research ethics. Underhill K, Soc Sci Med 2013 94 115 123 23597916
54. Treatment-related optimistic beliefs and risk of HIV transmission: a review of recent findings (2009-2012) in an era of treatment as prevention. Chen Y, Curr HIV/AIDS Rep 2012 10 79 88
55. Associations between the legal context of HIV, perceived social capital, and HIV antiretroviral adherence in North America. Phillips JC, Webel A, Rose CD, Corless IB, Sullivan KM, Voss J, Wantland D, Nokes K, Brion J, Chen W-T, Iipinge S, Eller LS, Tyer-Viola L, Rivero Méndez M, Nicholas PK, Johnson MO, Maryland M, Kemppainen J, Portillo CJ, Chaiphibalsarisdi P, Kirksey KM, Sefcik E, Reid P, Cuca Y, Huang E, Holzemer WL, BMC Public Health 2013 13 1 10.1186/1471-2458-13-1 23280303
56. A review of barriers and facilitators of HIV treatment among injection drug users. Wood E, Kerr T, Tyndall MW, Montaner JS, AIDS 2008 22 1247 1256 10.1097/QAD.0b013e3282fbd1ed 18580603
57. Social science and bioethics: the way forward. De Vries R, Turner L, Orfali K, Bosk C, Sociol Health Illn 2006 28 665 677 10.1111/j.1467-9566.2006. 00535.x 17184411
58. Don't solve the issues! Molewijk B, Widdershoven GA, Camb Q Healthc Ethics 2012 21 448 456 10.1017/S0963180112000229 22828039
59. Transcending the known in public health practice: the inequality paradox: the population approach and vulnerable populations. Frohlich KL, Potvin L, Am J Public Health 2008 98 216 221 10.2105/AJPH.2007.114777 18172133 (Pubitemid 351317555)
60. Rose's population strategy of prevention need not increase social inequalities in health. McLaren L, McIntyre L, Kirkpatrick S, Int J Epidemiol 2010 39 372 377 10.1093/ije/dyp315 19887510
61. Risk, risk groups and population health. Verweij M, Dawson A, Public Health Ethics 2012 5 213 215 10.1093/phe/phs032
62. Stigma and the ethics of public health: not can we but should we. Bayer R, Soc Sci Med 2008 67 463 472 10.1016/j.socscimed.2008.03.017 18502551
63. Could do better: research data sharing and public health. Dawson A, Verweij M, Public Health Ethics 2011 4 1 3 10.1093/phe/phr011
64. Fifteen million people on antiretroviral treatment by 2015: treatment as prevention. Granich R, Williams B, Montaner J, Curr Opin HIV AIDS 2013 8 41 49 10.1097/COH.0b013e32835b80dd 23188178
65. Expanded HAART coverage is associated with decreased population-level HIV-1-RNA and annual new HIV diagnoses in british columbia. Montaner JSG, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, Wood E, Kerr T, Shannon K, Moore D, Hogg RS, Barrios R, Gilbert M, Krajden M, Gustafson R, Daly P, Kendall R, Lancet 2010 376 532 539 10.1016/S0140-6736(10)60936-1 20638713
66. HIV/AIDS: guidelines chapter 7.1.1: when to start ART in adults and adolescents. World Health Organization, 2013 http://www.who.int/hiv/pub/ guidelines/arv2013/art/statartadolescents/en/index2.html ]
67. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: initiating antiretroviral therapy in treatment-naive patients. National Institutes of Health, 2013 http://www.aidsinfo.nih.gov/guidelines/html/ 1/adult-and-adolescent-arv-guidelines/10/initiating-antiretroviral-therapy-in- treatment-naive-patients ]
68. When to start antiretroviral therapy: the need for an evidence base during early HIV infection. Lundgren JD, Babiker AG, Gordin FM, Borges ÁH, Neaton JD, BMC Med 2013 11 148 10.1186/1741-7015-11-148 23767777
69. Can we stop AIDS with antiretroviral-based treatment as prevention? Mills EJ, Nachega JB, Ford N, Glob Health Sci Pract 2013 1 29 34 10.9745/GHSP-D-12- 00053